Genetic Testing
MeDIP Sequencing
MeDIP sequencing for research profiling of methylated-DNA enrichment; it is not an individual cancer-risk or treatment test.
About this service
MeDIP-seq enriches methylated DNA fragments before sequencing to study genome-wide methylation patterns. Enrichment-based profiles do not provide absolute methylation percentages at every base, and the result depends on input, antibody, controls and analysis. No clinical use is established by this listing.
Service highlights
- Research methylated-DNA enrichment and sequencing.
- Supports a defined epigenomics study.
- Not a base-resolution clinical methylation or cancer assay.
Who may consider it
- DNA-methylation researchers.
- Laboratories planning an epigenomics project.
What to expect
Confirm current project availability and quote. Clarify DNA input, whether enrichment/immunoprecipitation, library preparation, sequencing and analysis are included, and what controls/QC/data are provided. Confirm handling and turnaround; no SOP is supplied.
Scope and limitations
MeDIP sequencing provides enrichment-based research data. It does not diagnose cancer, determine a person's disease risk, establish causation or guide treatment.
Frequently asked questions
What is MeDIP sequencing?
It enriches methylated DNA fragments and sequences them to profile patterns for research.
Does it measure methylation at every base?
No. MeDIP-seq is enrichment-based and does not provide the same base-level measurement as bisulfite sequencing.
Can it diagnose cancer or guide care?
No clinical use is established. Confirm project availability, workflow and quote.